Table 1.
Patient demographic and clinical characteristics (per protocol set)
| PA21 group n = 100 | Sevelamer group n = 92 | P‐value | |
|---|---|---|---|
| Age (years), mean ± SD | 61.0 ± 11.7 | 60.8 ± 12.0 | NS† |
| Sex, n (%) | 0.048‡ | ||
| Male | 72 (72.0) | 53 (57.6) | |
| Female | 28 (28.0) | 39 (42.4) | |
| Prior use of phosphate binders, n (%) | – | ||
| Calcium carbonate | 71 (71.0) | 73 (79.3) | |
| Sevelamer hydrochloride | 33 (33.0) | 30 (32.6) | |
| Lanthanum carbonate | 47 (47.0) | 43 (46.7) | |
| Bixalomer | 8 (8.0) | 8 (8.7) | |
| Prior use of iron preparation, n (%) | 5 (5.0) | 4 (4.4) | – |
| Prior use of erythropoiesis stimulating agent, n (%) | 88 (88.0) | 86 (93.5) | – |
| Primary disease, n | – | ||
| Diabetic nephropathy | 32 | 20 | |
| Chronic glomerulonephritis | 43 | 42 | |
| Nephrosclerosis | 13 | 9 | |
| Polycystic kidney disease | 3 | 5 | |
| Others | 4 | 4 | |
| Unknown | 8 | 12 | |
| Mode of dialysis, n (%) | – | ||
| Haemodialysis | 87 (87.0) | 82 (89.1) | |
| Haemodiafiltration | 13 (13.0) | 10 (10.9) | |
| Dialysis vintage (months), mean ± SD | 104.9 ± 79.7 | 102.4 ± 90.6 | – |
| Serum phosphorus (mmol/L), mean ± SD | 2.51 ± 0.45 | 2.45 ± 0.39 | NS† |
| Corrected serum calcium (mmol/L), mean ± SD | 2.24 ± 0.15 | 2.22 ± 0.14 | NS† |
| Intact parathyroid hormone (ng/L), median (interquartile range) | 235 (176–339) | 282 (174–386) | 0.082†† |
†
Two‐sample t‐test;
‡
Fisher's exact test;
††
Two‐sample Wilcoxon test; NS, not significant